Guardant Health
GH
$17.06
Share price
-5.72%
Change (1 day)
-26.03%
Change (1 year)
Categories
Guardant Health is an American company developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors.
Guardant Health (GH) - Cash on Hand
Cash on Hand as of December 2023 : $1.16 B
According to Guardant Health
's latest financial reports the company has $1.16 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Guardant Health - Cash on Hand chart (from 2017 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $1.16 B | 15.57% |
| 2022-12-31 | $1.01 B | 8.41% |
| 2021-12-31 | $0.93 B | -48.03% |
| 2020-12-31 | $1.79 B | 243.32% |
| 2019-12-31 | $0.52 B | 24.79% |
| 2018-12-31 | $0.41 B | 89.3% |
| 2017-12-31 | $0.22 B | 132.34% |
| 2016-12-31 | $95.25 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Neogen NEOG | $0.23 B | -80.30% | 🇺🇸 USA |
 Natera NTRA | $0.87 B | -24.79% | 🇺🇸 USA |